Trading Signals: FOLD Stock Price Prediction and Forecast (Thu. May. 31, 2007 - Fri. Dec. 22, 2023)(Amicus Therapeutics Inc)
| FOLD latest price $12.2950 (2.67%) ($12.2950 - $12.3000) on Fri. Feb. 26, 2021. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 4.99% (three month average) | RSI | 14 | Latest Price | $12.2950(2.67%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | FOLD advances 0.2% a day on average for past five trading days. | Weekly Trend | FOLD declines -22.7% a week on average for past two weeks. | Market Behavior | Value stocks sell-off for large cap. Rotation from value to growth for small cap. | Correlated ETFs | Broad market will support FOLD advance at 0% a week (0% probability) IBB(57%) IWO(53%) XBI(52%) IWM(50%) IWC(49%) | Factors Impacting FOLD price | FOLD will decline at least -2.495% in a week (0% probabilities). VIXM(-30%) VXX(-14%) UUP(-12%) UNG(-6%) IGOV(-3%) | Explanation | The rally is not sustainable and not supported by the broad market. | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -2.495% (StdDev 4.99%) | Hourly BBV | 2.2 () | Intraday Trend | 0% | | | |
|
1 - 5 Day Possible Target | $-25.37(-306.34%) | Inflection Point | Yes | Resistance Level | $15.63 | 5 Day Moving Average | $12(2.46%) | 10 Day Moving Average | $12.08(1.78%) | 20 Day Moving Average | $15.63(-21.34%) | To recent high | -50.6% | To recent low | 3.7% | Market Cap | $3.175b | | | | Amicus Therapeutics, Inc. is a biotechnology company focused on discovering, developing, and delivering medicines for people living with rare metabolic diseases. The company is committed to advancing and expanding a pipeline of medicines for rare metabolic diseases, including a rare disease gene therapy portfolio. Amicus Therapeutics has a portfolio of product opportunities including the first and only approved oral precision medicine for people living with Fabry disease who have amenable genetic variants; a novel, clinical-stage, treatment paradigm for Pompe disease; and a rare disease gene therapy portfolio. The company was founded on February 4, 2002 and is headquartered in Cranbury, NJ. |